Skip to main content
. 2017 Apr 27;21(8):1468–1481. doi: 10.1111/jcmm.13073

Table 1.

Comparison of clinical manifestations and laboratory features between ID4 non‐hypermethylated and hypermethylated MDS patients

Patient's parameter Non‐hypermethylated (n = 50) Hypermethylated (n = 49) P value
Sex (male/female) 28/22 28/21 1.000
Age (years) 56 (14–85) 62 (20–86) 0.122
WBC (×109/l) 2.9 (1.3–19.5) 2.7 (0.9–82.4) 0.934
HB (g/l) 64 (26–128) 65 (38–118) 0.869
PLT (×109/l) 61.5 (3–1176) 47 (0–754) 0.746
BM blasts (%) 2.0 (0.0–16.5) 6.0 (0.0–27.0) 0.069
Cytogenetic classification
Good 36 (72%) 34 (69%) 0.677
Intermediate 9 (18%) 7 (14%)
Poor 2 (4%) 5 (10%)
No data 3 (6%) 3 (6%)
IPSS
Low 7 (14%) 2 (4%) 0.008
Int‐1 32 (64%) 26 (53%)
Int‐2 8 (16%) 9 (18%)
High 0 (0%) 9 (18%)
No data 3 (6%) 3 (6%)
Gene mutations
CEBPA (+/−) 2/47 0/47 0.495
IDH1/2 (+/−) 3/46 1/46 0.617
DNMT3A (+/−) 0/49 3/44 0.113
U2AF1 (+/−) 1/48 6/41 0.057
SF3B1 (+/−) 3/46 3/44 1.000

Median (range); WBC: white blood cells; HB: haemoglobin; PLT: platelet count; BM: bone marrow; IPSS: International Prognostic Scoring System; WHO: World Health Organization; RA: refractory anaemia; RARS: RA with ringed sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCMD‐RS: RCMD with ringed sideroblasts; RAEB: RA with excess of blasts.